Celgene halts trial of blood cancer drug

Celgene said it will discontinue a Phase III study of its blood cancer treatment Revlimid as a first-line treatment in elderly patients with B-cell chronic lymphocytic leukemia after it noticed more deaths in patients treated with Revlimid compared with patients taking chlorambucil. The FDA put the study on clinical hold last week. Celgene said it will examine data from the trial to determine whether the imbalance is due to factors such as age or comorbidities.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC